Industrial Policy & Trade Monitor· 2663 actions· ✨ 89 recent

At its 30 December 2025 regular session, Iraq's Council of Ministers, chaired by Prime Minister Mohammed Shia' Al-Sudani, approved two additional customs duties on imports from all countries of origin: a 40% additional duty on medical and industrial oxygen (gaseous and liquid forms), in effect for four years, and a 30% additional duty on imported yogurt (laban rayeb) and liquid milk. Both measures were framed as protecting domestic pharmaceutical/ industrial-gas production and local dairy manufacturing respectively, and take effect 120 days after issuance (29 April 2026) to give importers an adjustment window. Global Trade Alert logs the dairy duty as principally affecting Germany, Saudi Arabia and Türkiye as leading supplier origins, though the measure itself is non-discriminatory (applies to all origins).

On 25 December 2025 Shanghai's Huangpu District Science and Technology Commission and Investment Promotion Office jointly issued Huangkeweigui [2025] No. 2, "Several Measures on Focusing on Translational Medicine to Accelerate Industry-Medicine Integration Innovation and Development," effective 30 days after promulgation (4 February 2026 per Global Trade Alert tracking) and valid through 31 December 2027. The measures subsidize cell-and-gene therapy, mRNA, synthetic biology, regenerative medicine and digital-medicine R&D (up to CNY 2m/year per entity), platform/lab construction (up to 30% of investment, capped at CNY 2m), use of the district's translational-medicine national science facility (up to 50% of annual usage fee, capped at CNY 1m), and domestic Class 1 new-drug clinical trials (Phase I up to CNY 2m, Phase II up to CNY 5m, capped at CNY 50m/year per entity), plus annual support for biopharma industrial- park operators (up to CNY 2m/year).

On 19 December 2025 the Swiss Federal Assembly adopted in final vote the Federal Act on the Screening of Foreign Investments (Bundesgesetz über die Prüfung ausländischer Investitionen, Investitionsprüfgesetz / IPG; popularly the "Lex China", parliamentary business 22.035). The Act introduces Switzerland's first general ex-ante FDI-screening regime: acquisitions of control over Swiss companies active in security-critical sectors by foreign state-controlled investors require prior approval by SECO, with escalation to the Federal Council. The optional- referendum window runs until 17 April 2026; entry into force is not expected before 2027 once implementing ordinances are adopted. Critical sectors named in the Act include military and dual-use goods, electricity grids and generation, water supply, pharma and health, telecommunications, transport infrastructure and financial-market infrastructure.

India's DGFT issued Notification No. 50/2025-26 on 18 December 2025 (Gazette of India, Extraordinary, Part II, Section 3(ii)), inserting a new Policy Condition No. 08 under Chapter 29 of ITC (HS) 2022, Schedule-I (Import Policy). Imports of diluted Potassium Clavulanate below a CIF value of USD 77/kg, Potassium Clavulanate (KGA) below USD 180/kg, and specified clavulanic-acid-manufacture intermediates below USD 92/kg are reclassified from "Free" to "Restricted," requiring a DGFT import authorisation before Customs clearance. The measure took immediate effect and runs until 30 November 2026. It is aimed at countering low-priced Chinese potassium-clavulanate exports and protecting Indian bulk-drug fermentation capacity (Aurobindo Pharma and other domestic API makers) amid a global potassium-clavulanate supply glut.

Section 851 of the FY 2026 National Defense Authorization Act (P.L. 119-60), signed December 18, 2025, prohibits US federal agencies from procuring biotechnology equipment or services from designated "biotechnology companies of concern" (BCCs), and bars federal contractors from using such equipment/services in work performed under federal contracts, grants, or loans. The final enacted text ties initial BCC designations to DoD's existing §1260H Chinese-military-company list (which currently includes BGI and MGI, but not WuXi AppTec or WuXi Biologics) and directs OMB to designate additional BCCs within one year of enactment; operational prohibitions activate 60-90 days after FAR revision, with a five-year grandfather period for pre-existing contracts — enforcement is expected to begin in 2027-28. The legislation is the successor to H.R.8333 (118th Congress, House-passed September 2024 but stalled in the Senate before adjournment) and represents the first enacted US federal-procurement biotech-supply-chain-resilience statute.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

In the early hours of 11 December 2025 the Council of the EU and the European Parliament reached provisional political agreement in trilogue on the "EU Pharma Package" — the revised pharmaceutical Regulation (COM 2023/0131) and Directive (COM 2023/0132) — the most significant overhaul of EU pharmaceutical legislation in over two decades. The package replaces Directive 2001/83/EC (Community Code on medicinal products for human use) and Regulation (EC) 726/2004 (the EMA Regulation), and consolidates the orphan-medicine (Regulation 141/2000) and pediatric-medicine regulations into a single framework. Headline provisions: (i) a new "8+1(+1)(+1)" IP-incentive architecture — 8 years of regulatory data protection plus 1 year of market protection, with up to two additional 12-month extensions for products addressing unmet medical need or new active substances meeting comparative-trial conditions, capped at 11 years total; (ii) an EU-wide list of critical medicines under enhanced governance via the Medicines Shortages Steering Group (MSSG) and an EMA "list of critical shortages in the EU"; (iii) mandatory shortage-prevention plans on marketing-authorisation holders for prescription medicines and Commission-designated products; (iv) modernisation of clinical-trial requirements, environmental-risk assessment, antimicrobial stewardship, and a transferable-exclusivity-voucher (TEV) regime to incentivise novel antibiotic R&D. The COREPER I committee endorsed the compromise text on 6 March 2026 and final adoption by Parliament and Council is expected during summer 2026, with the regulatory framework becoming applicable in 2028.

The British Business Bank, the UK government's state-owned economic development bank, took a GBP 10.5 million (USD 13.9 million) equity stake in EpilepsyGTx, a UCL-spinout gene-therapy company, as part of a USD 33 million Series A financing round announced 10 December 2025. The round also included XGEN Venture and an unnamed global biopharmaceutical company; proceeds fund first-in-human Phase 1/2a trials of EpilepsyGTx's lead gene-therapy candidate EPY201 for focal refractory epilepsy.

On 9 December 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) issued the December 2025 batch expansion of its Mandatory List — a binding instrument requiring government entities, state-owned enterprises, and sub-contractors to source listed products exclusively from Saudi domestic manufacturers meeting the LCGPA-defined local-content threshold. The December 2025 expansion brings the list to approximately 1,444 national products across 16 sectors, effective 1 March 2026, with LCGPA targeting a total of approximately 2,000 products by end-2026. The Mandatory List operationalises the demand-side layer of Saudi Arabia's Vision 2030 / National Industrial Strategy (NIS) industrial-policy stack, directly restricting foreign-supplier access to Saudi annual government-procurement budgets estimated at SAR 500 billion+ across central government, Aramco, PIF-portfolio entities, Ma'aden, SEC, STC, Saudi Post, and Saudi Railway.

The European Commission approved German State aid of €47 million to Vetter Pharma, a family-owned contract development and manufacturing organisation (CDMO), to support a new aseptic fill-finish plant for injectable pharmaceuticals in Saarlouis, Saarland. The grant is part of a larger ~€480 million first construction phase of the site, which the Commission cleared under EU State aid rules citing job creation (up to 2,000 positions long-term), regional development in Saarland, and consistency with the EU Pharmaceutical Strategy for Europe's goal of securing affordable-medicines manufacturing capacity in the bloc.

Brazil's Foreign Trade Chamber Executive Committee (GECEX/CAMEX, under the Ministry of Development, Industry, Trade and Services) approved Resolução Gecex nº 823, at its 231st ordinary meeting (27 November 2025), rebalancing the country's ex-tarifário capital-goods duty-relief regime. Article 1 excludes ex-tarifário duty exemptions from Annex I of Resolução Gecex nº 322/2022 — reverting those products to the standard MFN import tariff. Article 2 grants new duty exemptions by adding items to the Annex Único of Resolução Gecex nº 780/2025. Article 3 amends the technical descriptions of six existing ex-tarifário line items (e.g. automatic pallet-strapping and film-wrapping machines, high-speed horizontal machining centres, injection moulding machines, genset generators) and Article 4 amends five more (including pharmaceutical carpule-filling systems and rotary offset printers). Global Trade Alert's analysis of the resolution counts 2,414 capital-goods products across 317 six-digit NCM headings as affected by the net exclusion/inclusion changes. The resolution took effect on DOU publication (5 December 2025) and was followed same-day by a minor rectification reorganising a handful of entries between Articles 3 and 4 without changing their technical specifications.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 821, de 1º de dezembro de 2025, amending Annex V (Letec — List of Exceptions to the Common External Tariff) and Annex X (List of Temporary Exceptions for Automotive Products under ACE 14) of the base tariff-nomenclature Resolução Gecex nº 272/2021. The resolution took effect on the date of its publication in the Diário Oficial da União. Global Trade Alert tracks the measure as four discrete tariff-line interventions bundled under one state act: (1) an import-tariff increase on butyl and sodium-polyacrylate chemical inputs, effective 5 December 2025; (2) a reduction of the import tariff to zero for a pharmaceutical product under NCM 3004.90.79, effective 5 December 2025; (3) a new import tariff-rate quota for a chemical/pigment product under NCM heading 3306.11, effective 5 December 2025; and (4) an import-tariff increase on 16 medical-device products under NCM 9018.90.99, effective 2 December 2025. Two of the four sub-measures are duty increases (harmful to importers) and two are duty reductions/new liberalising quotas — consistent with Gecex's routine periodic tariff-schedule maintenance cycle rather than a targeted trade-remedy or industrial-policy action.

The UK Department of Health and Social Care, delivered via Innovate UK, awarded more than GBP 54 million in government funding across eight R&D projects on 18 November 2025 through the Sustainable Medicines Manufacturing Innovation Programme, matched by more than GBP 20 million from industry (combined GBP 74m+). The programme is funded through the GBP 400 million VPAG Investment Programme, agreed under the 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG), and supports the manufacturing pillar of the UK's Modern Industrial Strategy Life Sciences Sector Plan. Funded projects include anaesthetic gas recovery/recycling (targeting ~GBP 5m annual NHS savings), converting spent nuclear fuel into radionuclide cancer therapies, CAR-T cell manufacturing scale-up (Royal Free Hospital), engineered bacteriophages for antibiotic resistance, and an AstraZeneca-led "Sustainable Future Factory" AI/robotics initiative.

On 13 November 2025, the United States and the Republic of Korea released a Joint Fact Sheet reaffirming the July 2025 announcement of the Korea Strategic Trade and Investment Deal — the first standalone US-Korea trade-and-investment agreement since the 2012 KORUS FTA. USTR issued the implementing Federal Register notice (90 FR 55964, Notice 2025-21940) on 3 December 2025, effective 4 December 2025, with retroactive HTSUS application to 1 November 2025 for autos and auto parts and to 14 November 2025 for reciprocal-tariff goods, timber, lumber, derivatives, and certain aircraft and aircraft parts. On the US tariff side: (i) the country-specific IEEPA reciprocal tariff on Korean originating goods is set at the higher of the KORUS FTA / MFN rate or 15% (parallel to the Japan and EU framework deals); (ii) the Section 232 tariffs on autos, auto parts, timber, lumber and wood derivatives are reduced to 15% (no incremental duty when the pre-existing KORUS/MFN rate already meets or exceeds 15%); (iii) Korean exports of qualifying goods on the Potential Tariff Adjustments for Aligned Partners (PTAAP) list are exempt from reciprocal tariffs (covering generic pharmaceuticals and unavailable natural resources); (iv) Section 232 pharmaceuticals capped at 15%; semiconductors granted MFN-style "no less favourable" treatment in any future sectoral deal. On the investment side, Korea commits to a USD 350bn package: USD 150bn into US shipbuilding ("Approved Investments") plus USD 200bn into US strategic industries via a separate Strategic Investments MOU, with annual currency-funding cap of USD 20bn. Non-tariff commitments include streamlined US biotech approvals on the Korean side, US meat and cheese market access, fair treatment for US digital services, removal of Korea's 50,000-unit cap on US vehicles meeting FMVSS, and joint WTO support for the moratorium on customs duties on electronic transmissions.

On 5 February 2026, USTR Ambassador Jamieson Greer and Argentine Foreign Minister Pablo Quirno signed in Washington the United States-Argentina Agreement on Reciprocal Trade and Investment (ARTI), formalising the framework jointly announced on 13 November 2025. The agreement is the first standalone bilateral trade-and-investment instrument concluded by the second Trump administration and the first FTA-style agreement signed under the post-IEEPA reciprocal-tariff architecture (Executive Order 14257, "Liberation Day"). On the US side, the ARTI sets out three tariff schedules: (i) Schedule 2A suspends additional reciprocal tariffs under EO 14257 for specified Argentine-origin goods (covering "unavailable natural resources" and non-patented pharmaceutical inputs); (ii) Schedule 2B grants a zero additional reciprocal tariff for designated Argentine agricultural products under EO 14360; and (iii) caps additional ad-valorem duties on other goods at 10% above MFN rates, inclusive of IEEPA reciprocal tariffs. On the Argentine side, illustrative tariff-rate quotas include duty-free access for 80,000 MT of US beef in calendar year 2026, 1,000 MT for cheese, 870 MT for almonds, 40 MT in-shell + 40 MT shelled for pistachios, 80,000 litres for wine (<2 L bottles), and preferential treatment for 10,000 motor vehicles meeting defined technical parameters. Argentina additionally commits to broader preferential market access on medicines, chemicals, machinery, information-technology products, medical devices, and a wide range of agricultural goods, alongside IP-enforcement upgrades (counterfeit/pirated-goods enforcement, patentability criteria, patent-backlog reduction, geographical indications) and investment-facilitation commitments that align Argentina's regime with US-preferred standards on regulatory cooperation, labour and environment.

On 12 November 2025 Beijing's Dongcheng District (via the Zhongguancun Science Park Dongcheng Zone Management Committee and the district Science and Technology Commission) issued Notice 东城园文〔2025〕12号, "Several Measures of Beijing Dongcheng District on Promoting Science and Technology Innovation Development," effective 12 December 2025 through 31 December 2028. The package tiers cash grants by milestone: up to RMB 100,000 for first-time high-tech-enterprise certification, RMB 1 million for first-to-market new technology/products, RMB 10 million for incubator and specialised industrial-park upgrades, and up to RMB 30 million for "chain-leader" enterprises or innovation-driving market entities judged to have significant regional radiating/spillover effect. Eligible sectors span new-generation information technology, cultural technology, pharmaceuticals and health, intelligent manufacturing, new materials, and green energy/environmental protection.

On 10 November 2025, China's Ministry of Commerce and four other departments issued Announcement No. 73 of 2025, adjusting the "Catalogue of Precursor Chemicals for Export to Specific Countries (Regions)" and adding the United States, Canada and Mexico to the "Specific Countries (Regions) Directory" under the Interim Provisions on the Management of Exports of Precursor Chemicals to Specific Countries (Regions). Exporters must now apply for a license before shipping 13 newly listed categories of precursor chemicals (used in illicit fentanyl and other synthetic-drug manufacture) to these three countries; exports of the same chemicals to other destinations remain unrestricted. The measure took effect the same day it was announced.

Bangladesh's Council of Advisers, chaired by Chief Adviser Prof. Muhammad Yunus, approved the National Logistics Policy 2025 on 6 November 2025 at its 47th meeting, replacing the annulled 2024 Awami League-era logistics policy. The framework spans 11 chapters and establishes a technology-driven, integrated, sustainable logistics ecosystem aimed at positioning Bangladesh as a leading regional trade and logistics hub by 2050. Two-tier governance architecture: a National Logistics Council (led by the Chief Adviser) for top-level coordination, and a National Logistics Development and Coordination Committee (led by the Chief Adviser's Principal Secretary) for implementation oversight across multimodal hubs, economic zones, international corridors, airports, river ports, sea ports, and land ports.

The UK Department of Health and Social Care updated its list of medicines that cannot be parallel-exported from the UK or hoarded, adding Nelarabine (250mg/50ml solution for infusion vials, used in leukaemia/lymphoma treatment) and removing ten products including Atracurium, Cisatracurium and Erythromycin, effective 6 November 2025. The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012 to protect domestic patient supply; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension. This is one of the DHSC's routine multi-times-per-year revisions to a standing list rather than a one-off policy action.

The Chongqing Municipal People's Government General Office issued "Several Measures for Chongqing's Full-Chain Support of High-Quality Innovative Drug Development" (Yu Fu Ban Fa [2025] No. 56) on 2025-11-01, a 25-point package of regulatory-fast-track and procurement-support measures for the municipal biopharma sector. It targets 1-3 newly approved innovative drugs per year through 2027 (10 total) and the cultivation of 3 pharmaceutical-innovation industrial complexes, 3 high-level innovation platforms, and 3 innovative-drug industry clusters. No direct subsidy or tax-incentive amount is disclosed in the published text — the package is operational (compressed clinical-trial and registration timelines, guaranteed hospital procurement) rather than a cash grant.

Russia's federal Industry Development Fund (FRP) disclosed a RUB 950 million (approx. USD 12 million) concessional loan under its "Development Projects" programme to biopharmaceutical company Nanolek LLC, financing purchase of high-tech equipment for Russia's first domestic human papillomavirus (HPV) vaccine production line. The facility, part of a RUB 7.5 billion total investment in the Orichevsky District of Kirov Region, opened 25-29 October 2025 and produces the "Tsegardeks" vaccine at an initial capacity of over 600,000 doses per year, rising to 3-3.5 million doses annually by 2027 with a planned second production line.

On 28 October 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) signed five localization and knowledge-transfer agreements on the sidelines of the Global Health Exhibition 2025, covering domestic manufacture and technology transfer for the biologic drugs etanercept and adalimumab (both used to treat chronic inflammatory / autoimmune conditions) and for orthopedic trauma implants. The adalimumab agreement was signed separately with Boston Oncology Arabia and Tabuk Pharmaceuticals. Boston Oncology's own disclosure of its adalimumab/ etanercept agreement (announced 4 November 2025) put the combined economic impact at over SAR 1.2 billion in cumulative GDP contribution and approximately 500 direct jobs, with production sited at its Sudair Industrial City facility (USFDA/EMA/SFDA-standard). Global Trade Alert's tracking of the same state act records seven counterparties in total (Boston Oncology, Tabuk Pharmaceuticals, Rameem Medical, Bio Vision, Sudair Pharma, Almana Company, and an additional pharma manufacturer), consistent with LCGPA's practice of bundling several related product-localization signings into one event.

The UK Office for Life Sciences (OLS) launched the Life Sciences Large Investment Portfolio (LSLIP), a subsidy scheme worth up to GBP 570 million running from implementation in November 2025 to March 2030. The scheme provides direct grants, capped at GBP 130 million per award, to UK-registered private-sector companies committing to invest GBP 250 million or more over three years in domestic manufacturing or commercial R&D across three subsectors: human medicines (APIs and finished products), medical diagnostics, and MedTech. The scheme was referred to the CMA's Subsidy Advice Unit on 21 August 2025, which published its advisory report on 2 October 2025 ahead of the scheme's launch.

India's DGFT issued Notification No. 41/2025-26 on 10 October 2025, inserting a new import policy condition under Chapter 29 of ITC (HS) 2022, Schedule-I (Import Policy) for Sulfadiazine API (ITC-HS codes 29359013 and 29359090). Imports with a declared CIF value below Rs. 1,774 per kilogram are reclassified from "Free" to "Restricted," requiring a DGFT import authorisation before Customs clearance. The measure took immediate effect and runs until 30 September 2026, aimed at curbing low-priced imports — Global Trade Alert records China, France and Israel among the affected exporters — while protecting domestic API manufacturers.

On 6 October 2025, the US Treasury's Office of Foreign Assets Control (OFAC) designated 8 Mexican individuals and 12 Mexico-based companies under Executive Order 14059 for supplying fentanyl precursor chemicals and laboratory equipment to the Sinaloa Cartel's "Los Chapitos" faction, led by fugitive brothers Archivaldo Ivan and Jesus Alfredo Guzman Salazar (sons of Joaquin "El Chapo" Guzman Loera). The network is centred on Sumilab, a chemical and lab-equipment supplier previously sanctioned by OFAC in May 2023, which restructured through affiliated pharmaceutical, laboratory, chemical, cleaning-supply and real-estate front companies to continue operating after the earlier designation. All property and interests in property of the designated persons within US jurisdiction or held by US persons are blocked, and US persons are generally prohibited from transacting with them.

China's State Council promulgated Order No. 818 on 28 September 2025 (effective 1 May 2026), establishing a comprehensive dual-track regulatory framework for biomedical new technologies — defined as techniques operating at the cellular or molecular level not yet clinically applied in China, covering cell therapy, gene editing, CAR-T, stem-cell, xenotransplantation, brain-computer interfaces, and nucleic-acid therapies. The regulation creates two parallel pathways: a traditional NMPA drug/device registration route and a new NHC-supervised clinical-research-to-commercialization track applicable to highly personalised or rare-disease therapies meeting staged safety and efficacy thresholds. Commercialisation under the NHC track is initially restricted to accredited Grade-3A medical institutions without full NMPA marketing approval, potentially accelerating patient access for qualifying technologies by 5–8 years relative to the standard registration pathway.

On 26 September 2025, Japan's Minister of Finance Katsunobu Kato announced the establishment of the Japan Strategic Investment Facility, a JBIC-administered financing vehicle operationalising the USD 550bn investment pledge from the July 2025 US-Japan tariff and investment agreement. The facility launched 1 October 2025 and runs through March 2029, supporting the overseas expansion of Japanese companies across nine economic-security sectors: semiconductors, pharmaceuticals, steel, shipbuilding, critical minerals, aviation, energy, automobiles, and AI/quantum technology. Funding draws on three sources — dollar-denominated JBIC bonds, yen-denominated Japanese government loans to JBIC, and a "supplemental" transfer from Japan's USD 1.324tn foreign-currency reserves — with private-sector loans and NEXI-backed loan guarantees supplementing JBIC's own financing.

The UK Department for Science, Innovation and Technology and the Office for Life Sciences launched the Life Sciences Transformational R&D Investment Fund (TRIF) Pilot, a GBP 50 million (approx. USD 67.4 million) capital grant scheme for large-scale R&D projects in the life sciences sector. Only projects with total costs of at least GBP 100 million qualify, with grants typically covering 10-20% of total project costs. The pilot runs on a rolling-application basis until 31 March 2028 or until funding is exhausted.

The European Commission adopted Implementing Regulation (EU) 2025/1901 on 22 September 2025, imposing definitive anti-dumping duties on imports of glyoxylic acid (CAS 298-12-4, purity ≥95%, CN code ex 2918 30 00, TARIC 2918300013) originating in China for five years. Duty rates are differentiated by exporter: Hubei Hongyuan 29.2%, Xinjiang Guolin 130.0%, other cooperating producers 64.0%, and all non-cooperating Chinese imports 210.5%. The regulation definitively collects provisional duties previously imposed under Regulation (EU) 2025/591 (up to 280.3% provisional rates) from 24 March 2025.

India's DGFT issued Notification No. 30/2025-26 on 18 September 2025, inserting a new import policy condition under Chapter 29 of ITC (HS) 2022, Schedule-I (Import Policy) for ATS-8 — (4R-Cis)-1,1-Dimethylethyl-6- cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate (HS 2932.99), the key synthesis intermediate for Atorvastatin, a National List of Essential Medicines cholesterol-lowering statin API. Imports with a declared CIF value below USD 111/kg are reclassified from "Free" to "Restricted," requiring a DGFT import authorisation before Customs clearance. The measure took immediate effect and runs until 30 September 2026. Global Trade Alert records China, Argentina and Canada among the affected exporters; global merchant-market ATS-8 supply is concentrated among Chinese producers.

Brazil's Câmara de Comércio Exterior (Gecex) approved Resolução nº 788, de 10 de setembro de 2025, amending Annex IV of the base tariff-nomenclature resolution (Gecex nº 272/2021) under the Mercosur supply-shortage tariff-reduction mechanism (Mercosur GMC Resolution nº 49/19). The resolution establishes six new duty-free (0%) temporary import tariff-rate quotas: spray-dry detergent powder (800,000 t/year), vitamin B12 (20 t/year), the cell therapy Tisagenlecleucel (48 units), sulphur black dye (6,000 t/year), elastomultiester bicomponent polyester synthetic filament (1,100 t/year), and high-voltage (345kV-class) electrical cable (1,550 t/year). Quotas run for one year from their individual validity start dates, which range from 15 September 2025 to 22 January 2026 depending on product, granting duty-free entry within volume caps where Mercosur-region supply is judged insufficient.

The European Investment Bank (EIB) signed a EUR 400 million loan agreement with Fresenius on 8 September 2025 in Bad Homburg, Germany, to finance research, development and innovation activities and capacity expansion for Fresenius Kabi's manufacturing of biosimilars, generic drugs, infusion therapies, clinical nutrition products, and associated medical devices across EU member states. The financing is explicitly framed by both parties as strengthening the resilience of European pharmaceutical production and security of supply for EU healthcare systems.

The British Business Bank, the UK government's economic development bank, announced an GBP 8 million equity investment into NRG Therapeutics Ltd on 8 September 2025 as part of an oversubscribed GBP 50 million (USD 67 million) Series B financing round. NRG Therapeutics develops small-molecule mitochondrial permeability transition pore (mPTP) inhibitors for neurodegenerative diseases including ALS/MND and Parkinson's. The round was led by SV Health Investors' Dementia Discovery Fund, with participation from M Ventures, Novartis Venture Fund, Criteria Bio Ventures, and existing investors Omega Funds and Brandon Capital; a British Business Bank representative joined NRG's board.

President Trump signed Executive Order 14345 on 4 September 2025, implementing the July 2025 US-Japan trade agreement by setting a 15% baseline ad-valorem tariff on nearly all Japanese goods — raising any Column 1 (MFN) duty rate below 15% up to that floor, including on agricultural lines such as cereals, vegetables, and fruits and nuts. The modification applies retroactively to Japanese products entered for consumption on or after 12:01 a.m. EDT, 7 August 2025, and supersedes the higher 24% country-specific reciprocal rate Japan faced under the April 2025 "Liberation Day" schedule. Aerospace products are exempted entirely, autos/auto parts receive the same 15% treatment (down from a separate 25% Section 232 rate), and Japan committed to $550bn in US investment and $8bn/year in additional US agricultural purchases (rice, corn, soybeans, fertilizer, bioethanol) as consideration.

On 3 September 2025, the U.S. Treasury's Office of Foreign Assets Control (OFAC) designated Guangzhou Tengyue Chemical Co., Ltd., a China-based chemical manufacturer, along with two of its representatives, Huang Xiaojun and Huang Zhanpeng, pursuant to Executive Order 14059 for materially contributing to the international proliferation of illicit drugs. The company was found to have manufactured and sold synthetic opioids — including nitazenes — and analgesic cutting agents such as xylazine and medetomidine to U.S. buyers. The designation blocks all U.S.-person property and transactions involving the three designated persons and any entity 50%-or-more owned by them; the FBI simultaneously announced a related federal indictment against Guangzhou Tengyue, the two individuals, and roughly 22 other China-based individuals and businesses for conspiracy to commit drug trafficking.

On 29 August 2025 the Pinggu District (Beijing) Science, Technology and Economic Informatization Bureau issued "Several Measures to Promote the High-Quality Development of High-End Manufacturing in Pinggu District" (平谷区促进高端制造业高质量发展若干措施), published to the district government portal on 25 September 2025 with a two-year validity period. The scheme offers manufacturers registered and operating in Pinggu a stack of output-growth, R&D, smart-factory, green-transformation, pharma/medical- device, auto-parts-supply-chain, and synthetic-biology subsidies, with per-recipient caps ranging from RMB 200,000 up to RMB 10 million for qualifying pharmaceutical/medical-device innovators.

Brazil's Câmara de Comércio Exterior executive committee (Gecex) approved Resolução nº 779, de 28 de agosto de 2025, amending Annex V of the base tariff-nomenclature resolution (Gecex nº 272/2021). The resolution opens a new one-year, 25,000-tonne tariff-rate quota at a reduced 3.6% duty for chromium sulfate powder (NCM 2833.29.60), adds two natural-rubber lines (TSNR and granulated/pressed rubber, NCM 4001.22.00 / 4001.29.20) to the reduced-tariff annex at 10.8% with no volume cap, and simultaneously removes three antibiotic active-ingredient import lines — piperacillin/ tazobactam, ceftazidime, and meropenem (NCM 3004.10.19, 3004.20.59, 3004.20.99) — from the same reduced-tariff annex, reverting them to the standard (higher) MFN duty.

South Korea's National Assembly passed an amendment to the Korea Development Bank (KDB) Act on 2025-08-27 (428th session, 3rd plenary sitting, 164-1 with 164 votes in favour of 165 cast), raising KDB's statutory capital ceiling from KRW 30 trillion to KRW 45 trillion and creating a new "Advanced Strategic Industry Fund" inside KDB. The fund is capitalised at KRW 50 trillion or more over five years via low-rate government-guaranteed bonds and is earmarked for the ten officially designated advanced strategic industries (AI, semiconductors, bio/vaccines, defense, robotics, hydrogen, secondary batteries, displays, future mobility) via cheap loans and equity investment. KDB intends to use the fund as seed capital for a wider "National Growth Fund" that blends in private and pension capital to reach KRW 100 trillion+ in total strategic-industry financing over five years.

Act L of 2025 (2025. évi L. törvény) is the Hungarian National Assembly statute that elevates a set of war-emergency government decrees — including the foreign-investment screening regime previously embedded in Government Decree 561/2022 — to permanent statutory level. Promulgated in Magyar Közlöny and entered into force on 19 August 2025, the Act preserves Hungary's "Second Regime" of FDI screening operating in parallel with the General Regime (which implements EU Reg 2019/452 since 2019). The Second Regime applies to a broad set of strategic sectors — energy, transport, communications, telecoms, pharmaceuticals, food processing, defence, financial services and healthcare — and requires approval from the Minister of National Economy for qualifying acquisitions (direct or indirect majority, ≥5% interest, ≥3% in listed companies, or ownership/operation of strategic infrastructure) where transaction value reaches HUF 350 million (~EUR 890,000). Notification is due within 10 days of signing; the MoE originally had 30 business days (extendable +15 calendar days). The Act also entrenches the Hungarian state right of first refusal on photovoltaic generation companies (NACE 35.11'08, excluding sub-50 kVA household installations), exercised through MNV Zrt. The Special Regime is structurally distinct from the General Regime and represents Hungary's peer to the German AWG §§55-62, French Décret 2014-479, Dutch Wet Vifo, and Italian Golden Power. Amended by Act XCIII of 2025 (in force 17 December 2025), which extended the MoE screening deadline to 45 business days and excluded bank-financing security arrangements from notification.

The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.

On 13 August 2025 President Trump signed an Executive Order ("Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve", Federal Register Doc. 2025-15823, published 19 August 2025) directing the HHS Assistant Secretary for Preparedness and Response (ASPR) to refill and operationalise the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). Within 30 days, ASPR must compile an initial list of 26 essential drugs, account for available funding, and acquire and maintain a six-month supply of the corresponding APIs. Within 90 days, ASPR must deliver an expanded list of up to 86 essential medicines and medical countermeasures plus a plan to source those APIs from domestic manufacturers, and within 120 days (subject to appropriations) ready the existing SAPIR repository and submit a proposal and cost estimate for opening a second repository. The order prioritises domestically manufactured APIs in federal procurement and reserve build-out and directs interagency coordination across HHS/ASPR, FDA, DoD (Industrial Base Fund / Defense Production Act Title III), and the Department of Commerce.

Wisconsin Governor Tony Evers and the Wisconsin Economic Development Corporation (WEDC) announced on 5 August 2025 a package of up to $100 million in performance-based Enterprise Zone state tax credits to support Eli Lilly and Company's $4 billion expansion of its parenteral (injectable) drug manufacturing site in Bristol, Kenosha County. The credits are split between up to $18 million for job creation and up to $82 million for capital investment, contingent on Lilly creating at least 700 jobs and making at least $2.2 billion in qualifying capital investment, with the allocation period running through 2036.

The Cabinet of Ministers of the Republic of Armenia, chaired by Deputy Prime Minister Mher Grigoryan, approved the 2025-2030 Strategic Plan for Promoting Exports of the Republic of Armenia and its accompanying Action Plan on 31 July 2025. The Strategy targets a 1.7-fold increase in total Armenian exports to USD 16.9 billion by 2030 (USD 10.3 billion services + USD 6.6 billion goods), with an implementation envelope of approximately AMD 98 billion (~USD 250 million). It designates critical minerals (copper-molybdenum concentrates, gold, antimony, emerging rare-earth-element zones), IT and tech services, agri-processing, and green-transition equipment as priority export categories, and operationalises Armenia's ongoing reorientation of export geography away from Russia/EAEU toward EU, US, Gulf, and Asian markets.

On 27 July 2025, President Trump and European Commission President Ursula von der Leyen reached political agreement at Turnberry, Scotland, on a Framework Agreement on Reciprocal, Fair and Balanced Trade. The framework was formalised in a Joint Statement published on 21 August 2025 by the White House and DG TRADE. The deal establishes a 15% all-inclusive (MFN + Section 232) US tariff ceiling on the vast majority of EU originating goods — including autos, pharmaceuticals, semiconductors, lumber, and chemicals — replacing the threatened 20-30% reciprocal tariff trajectory under EO 14257 (April 2025). Steel and aluminium are excluded from the 15% ceiling and remain at the 50% Section 232 rate pending negotiation of a quota solution. In return, the EU commits to: (i) eliminate tariffs on all US industrial goods, (ii) preferential market access for a wide range of US agricultural and seafood products, (iii) suspension of its rebalancing countermeasures under Reg 2025/778 (suspension effective 7 August 2025), (iv) expected energy offtake of $750bn (LNG, oil, nuclear) through 2028, (v) at least $40bn in US AI chip purchases, and (vi) facilitation of $600bn in additional EU corporate investment into the US through 2028. Effective from 1 September 2025, the US applies MFN-only treatment (no 15% top-up) to: aircraft and parts, generic pharmaceuticals and ingredients, chemical precursors, cork, and certain unavailable natural resources. The framework is not legally binding but anchors the bilateral architecture; it is the largest-economy ART-programme deal alongside US-UK, US-Japan, US-Korea, US-Taiwan, and US-Indonesia.

The National Reconstruction Fund Corporation (NRFC), Australia's AUD 15 billion sovereign industrial-financing vehicle, committed AUD 150 million to Brandon Capital's Brandon BioCatalyst 6 (BB6) fund, announced 24 July 2025. Brandon Capital — Australasia's largest life-sciences venture capital manager, with over AUD 1 billion under management — closed BB6 at AUD 439 million total, with the NRFC contribution the largest single commitment. The fund backs early- and late-stage Australian medical-science companies developing therapeutics, medical devices and vaccines, with roughly one-third earmarked for early-stage ventures and the remainder for late-stage clinical development and commercialisation. NRFC frames the deal as building sovereign medical-manufacturing and R&D capability and keeping Australian biotech IP and jobs onshore rather than migrating offshore for follow-on capital.

The UK Department of Health and Social Care added five tuberculosis-treatment antimicrobials to its list of medicines that cannot be parallel-exported from the UK or hoarded, effective 17 July 2025: Rifampicin capsules/powder and solvent for infusion (all strengths), Pyrazinamide 500mg tablets, Rifampicin + Isoniazid 300mg/150mg tablets, Rifampicin + Isoniazid + Pyrazinamide 120mg/50mg/300mg tablets, and Voractiv tablets (all strengths). The restriction is issued under regulation 43(2) of the Human Medicines Regulations 2012; breach constitutes a wholesale dealer licence violation enforceable by the MHRA with licence suspension.

The Polish Sejm passed the Act of 9 July 2025 amending the Act of 24 July 2015 on the Control of Certain Investments, signed by the President on 21 July 2025 and effective 24 July 2025. The amendment removes the time-limited "Specialised Rules" tier (introduced in 2020 under the Anti-COVID Shield) and makes Poland's FDI screening regime permanent. Review competence is transferred from the President of UOKiK (the competition authority) to the minister responsible for economic affairs (currently the Minister of Finance and Economy), and a new trigger covering "an international situation distorting the market or competition" is added alongside the existing public-order, security and health grounds.

The European Investment Bank signed a EUR 150 million loan agreement with Italian pharmaceutical group Alfasigma SpA on 8 July 2025 to finance the company's 2025-2027 research and development programme in rare diseases and specialty care (gastroenterology/hepatology, vascular medicine, rheumatology). The EIB framed the operation as part of its agenda to bolster competitiveness and innovation in the European healthcare sector. Global Trade Alert logged the announcement and implementation date as 27 June 2025 (state-act 92597); the EIB's own press release places the signing on 8 July 2025.

France's Ministry of Agriculture, acting through FranceAgriMer, opened a EUR 45 million call for projects on 30 June 2025 to fund research and development of alternatives to chemical crop protection products (phytopharmaceuticals). The call — part of the PARSADA strategic plan launched in spring 2023 to anticipate a potential EU-level withdrawal of active substances — funds 3-to-5 year projects at 40-100% of eligible costs, capped at EUR 7.5 million per project, across eight agricultural sectors. Applications are accepted on a rolling basis through 31 December 2026.

Minister of Trade Regulation No. 20 of 2025, signed by Minister Budi Santoso on 30 June 2025 and effective 29 August 2025 (60 days after promulgation), reorganises Indonesia's import regime for chemicals, Hazardous Materials (B2), and a defined set of mining and energy inputs. The regulation revokes Permendag 8/2024 and requires holders of designated importer status (Importir Terdaftar / Importir Produsen) to secure an Import Approval (Persetujuan Impor) plus a post-arrival Surveyor Report (Laporan Surveyor) for an eleven-cluster commodity bundle including lubricant raw materials, cement clinker and cement, rough diamonds, non-pharmaceutical precursors, crude oil and natural gas, nitrocellulose, commercial-industrial explosives, ozone-depleting substances, hydrofluorocarbons, B2, and certain other chemicals (BKT). It is one of nine commodity-cluster Permendags issued the same day under the Prabowo administration's umbrella import-policy deregulation package.